5 recruiting, 5 unknown, 3 completed, 2 not yet recruiting. 6 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Completed 1, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Unknown 1 |
Follow Myelosuppression: new trials by email Literature Review of Myelosuppression trials Research Report on Myelosuppression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC), Myelosuppression | Recruiting | Nanfang Hospital, Southern Medical University | 1782 | 2026-08-26 | 2026-09-15 | |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC Trilaciclib combined with Docetaxel - Non-Small Cell Lung Cancer, Myelosuppression | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 33 | 2025-05-09 | 2025-06-08 |
| A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib Chemotherapy, Trilaciclib Injection [Cosela] - Ewing Sarcoma, Myelosuppression | Phase 2 | Recruiting | Fudan University | 22 | 2024-10-31 | 2024-11-21 |
| Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients No intervention; Observational study - Myelosuppression | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 1000 | 2024-10-20 | 2024-10-16 | |
| Trilaciclib Prevents Myelosuppression With Chemoradiotherapy Trilaciclib - Myelosuppression | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-06-26 | 2024-09-24 |
| A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC 5-fu, Lobaplatin, Placebo - Nasopharyngeal Carcinoma, Leucogen | Phase 3 | Not yet recruiting | Sun Yat-sen University | 132 | 2023-04-01 | 2023-03-22 |
| A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations Empegfilgrastim - Solid Tumor, High-Risk Cancer | Unknown | Moscow Clinical Scientific Center | 285 | 2020-04-28 | 2021-06-02 | |
| Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia PEG-rhG-CSF - Chemotherapy-induced Neutropenia, Myelosuppression | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 1500 | 2019-02-13 | 2019-02-19 | |
| Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions Myelosuppression, Lactic Acidosis | Unknown | National Taiwan University Hospital | 1000 | 2016-11-01 | 2022-02-10 | |
| Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia Myelo001, Placebo - Chemotherapy-Induced Neutropenia, Myelosuppression | Phase 2 | Completed | Myelo Therapeutics GmbH | 137 | 2016-03-01 | 2017-11-24 |
| Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment - Myelosuppression | Completed | Taichung Tzu Chi Hospital | 35 | 2015-07-01 | 2022-07-01 | |
| Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy Medical Chart Review - Malignant Glioma, Myelosuppression | Terminated | Wake Forest University Health Sciences | 18 | 2015-02-01 | 2018-07-03 | |
| Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy Profonycia - Myelosuppression | Not applicable | Unknown | Ziv Hospital | 50 | 2007-09-01 | 2007-09-05 |
| Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma platelet transfusion - Hemato-Oncologic Patients, Myelosuppression | Phase 3 | Completed | Sanquin Research & Blood Bank Divisions | 180 | 2003-10-01 | 2007-02-27 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Nasopharyngeal Carcinoma (2) · Thrombocytopenia (2) · Acidosis, Lactic (1) · Febrile Neutropenia (1) · Gastrointestinal Neoplasms (1) · Glioma (1) · Leukopenia (1) · Neoplasms (1) · Neutropenia (1) · Peripheral Nervous System Diseases (1) · Sarcoma, Ewing (1) · Small Cell Lung Carcinoma (1) · Thoracic Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (8) · Neoplasms by Histologic Type (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Cytopenia (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms, Glandular and Epithelial (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Blood Platelet Disorders (2)
trilaciclib (4) · Drug Therapy (2) · pegylated granulocyte colony-stimulating factor (2) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Docetaxel (1) · Etoposide (1) · Fluorouracil (1) · Leyk (1) · Observation (1) · Platelet Transfusion (1) · Radiotherapy (1) · lobaplatin (1)
The First Affiliated Hospital of Xiamen University (2) · Affiliated Hospital of Nantong University (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Moscow Clinical Scientific Center (1) · Myelo Therapeutics GmbH (1) · Nanfang Hospital, Southern Medical University (1) · National Taiwan University Hospital (1) · Sanquin Research & Blood Bank Divisions (1) · Sun Yat-sen University (1) · Taichung Tzu Chi Hospital (1) · The First Affiliated Hospital of Xinxiang Medical College (1) · Wake Forest University Health Sciences (1)
China (9) · Germany (1) · Israel (1) · Netherlands (1) · Russia (1) · Taiwan (1) · United States (1)
Alexey Tryakin, MD, PhD, professor (1) · Dirk Pleimes, MD (1) · Glenn Lesser (1) · Inna Ganshina, MD, PhD (1) · Lei Deng, PhD (1) · Lyudmila Zhukova, MD, PhD, professor (1) · Mikhail Fedyanin, MD, PhD, professor (1) · Shu-Wen Lin (1) · Svetlana Khokhlova, MD, PhD (1) · Zidan Jamal, Prof (1)
2015 (1), P30CA012197 (1)